Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
Номер патента: MY202279A
Опубликовано: 22-04-2024
Автор(ы): Ashwin BASARKAR, Chakravarthy Nachu NARASIMHAN, Manoj K Sharma, Mohammed Shameem, Ramesh S Kashi, Sarita MITTAL, Soumendu Bhattacharya, Wendy BENJAMIN, William P Forrest Jr, Yogita Krishnamachari
Принадлежит: Merck Sharp & Dohme LLC
Опубликовано: 22-04-2024
Автор(ы): Ashwin BASARKAR, Chakravarthy Nachu NARASIMHAN, Manoj K Sharma, Mohammed Shameem, Ramesh S Kashi, Sarita MITTAL, Soumendu Bhattacharya, Wendy BENJAMIN, William P Forrest Jr, Yogita Krishnamachari
Принадлежит: Merck Sharp & Dohme LLC
Реферат: The invention relates to stable formulations of antibodies against human programmed death receptor PD- I, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti- PD-I antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
Номер патента: SG11201910182RA. Автор: Mohammed Shameem,Soumendu Bhattacharya,Ramesh Kashi,Manoj Sharma,Yogita Krishnamachari,Chakravarthy Nachu NARASIMHAN,Ashwin BASARKAR,Wendy BENJAMIN,Sarita MITTAL,William Forrest. Владелец: Merck Sharp & Dohme. Дата публикации: 2019-11-28.